Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects

• Status: Completed
• Trial end date: 2013-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Midazolam

Criteria

Inclusion Criteria:

• Healthy male and female subjects aged 18 to 49 years, with BMI of 18-32 kg/m²

• Women who are not of childbearing potential

Exclusion Criteria:

• Women of childbearing potential

• Women who are pregnant, breastfeeding, or unwilling or unable to use an acceptable method of birth control.

• Gastrointestinal disease that may impact the absorption of study drug

• History of any chronic respiratory disease (asthma, COPD)